BIBLIOGRAPHY

BIBLIOGRAPHY

Abraham RJ, Bullock E, Mitra SS. "Physical properties of alkyl pyrroles and their salts." Can J Chem 1959; 37:1859. (Reported in pKa Masterfile, Biobyte Inc., 2005)

Ali I, Welch MA, Lu Y, Swaan PW, Brouwer KLR. “Identification of Novel MRP3 Inhibitors Based on Computational Models and Validation Using an In Vitro Membrane Vesicle Assay.” Eur J Pharm Sci. 2017, 103:52-59.

Ames BN, McCann J, Yamasaki E. "Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test." Mutation Res 1975; 31:347-364.

Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12:413-20.

Anderson JSM, Junia Melin J, Ayers PW. "Conceptual Density-Functional Theory for General Chemical Reactions, Including Those That Are Neither Charge- nor Frontier-Orbital-Controlled. 1. Theory and Derivation of a General-Purpose Reactivity Indicator." J Chem Theory Comput 2007; 3:358–374 (DOI: 10.1021/ct600164j).

Arena VC, Sussman NB, Mazumdar S, Yu S, Macina OT. “The utility of structure-activity relationship (SAR) models for prediction and covariate selection in developmental toxicity: comparative analysis of logistic regression and decision tree models.” SAR and QSAR in Environ Res 2004; 15:1-18.

Arnot JA, Gobas FAPC. “A review of bioconcentration factor (BCF) and bioaccumulation factor (BAF) assessments for organic chemicals in aquatic organisms.” Environ Rev 2006; 14: 257-297.

Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. “The influence of nonspecific microsomal binding in apparent intrinsic clearance, and its prediction from physicochemical properties” Drug Metab Dispos 2002; 30:1497-1503.

Austin PD, Barton P, Mohmed S, and Riley RJ. “The binding of drugs to hepatocytes and its relationship to physicochemical properties.” Drug Metab Dispos 2005; 33: 419-425.

Avdeef A. "Predicting Solubility of New Drugs. Handbook of Critically Curated Data for Pharmaceutical Research.", CRC Press, Boca Raton, FL, 2024.

Barr JT, Lade JM, Tran TB,  Dahal UP. “Fraction Unbound for Liver Microsome and Hepatocyte Incubations for All Major Species Can Be Approximated Using a Single-Species Surrogate.“ Drug Metab Dispos 2019; 47:419-423.

Barrow JC, Nantermet PG, Selnick HG, Glass KL, Rittle KE, Gilbert KF, Steele TG, Homnick CF, Freidinger RM, Ransom RW, Kling P, Reiss D, Broten TP, Schorn TW, Chang RSL, O’Malley SS, Olah TV, Ellis JD, Barrish A, Kassahun K, Leppert P, Nagarathnam D, Forray C. In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α 1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia. J Med Chem 2000;43(14):2703–2718.

Bakatselou V, Oppenheim RC, and Dressman JB. "Solubilization and wetting effects of bile salts on the dissolution of steroids." Pharm Res 1991; 8:1461-1469.

Barlaam B, De Savi C, Dishington A, Drew L, Ferguson AD, Ferguson D, Gu C, Hande S, Hassall L, Hawkins J, Hird AW, Holmes J, Lamb ML, Lister AS, McGuire TM, Moore JE, O’Connell N, Patel A, Pike KG, Sarkar U, Shao W, Stead D, Varnes JG, Vasbinder MM, Wang L, Wu L, Xue L, Yang B, Yao T. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement. J Med Chem 2021;64(20):15189–15213.

Beaumont K, Webster K, Gardner I, Dack, K. “Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist.” Curr Drug Metab 2003, 4:461-485.

Beck B, Breindl A, and Clark T. "QM/NN QSPR Models with Error Estimation: Vapor Pressure and LogP." J Chem Inf Comput Sci 2000; 40:1046-1051.

Beedham C, Critchley DJP, Rance DJ. "Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon." Arch Biochem Biophys 1995, 2:481-490.

Betts A, Atkinson F, Gardner I, Fox D, Webster R, Beaumont K, Morgan P. Impact of Physicochemical and Structural Properties on the Pharmacokinetics of a Series of α1 L -Adrenoceptor Antagonists. Drug Metab Dispos 2007;35(8):1435–1445.

Bjerrum N. "Dissoziationkonstanten von mehrbasischen Sauren und ihre Anwendung zur Berechnung molekular Dimensionen." Z. Phys. Chem., Stoechiom. Verwandtschaftsl. 1923; 106:219-241.

Bemis GW, Murcko MA. “The Properties of Known Drugs. 1. Molecular Frameworks.” J Med Chem 1996; 39:2887-2893.

Bennett KP, Embrechts MJ. “An Optimization Perspective on Kernel Partial Least Squares Regression.” In: Advances in Learning Theory: Methods, Models and Applications. NATO Science Series III: Computer & Systems Sciences, Vol. 190, IOS Press Amsterdam, 2003): pp 227-250.

Bickerton, G., Paolini, G., Besnard, J et al. “Quantifying the chemical beauty of drugs” Nature Chem 2012, 4:90–98.

Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins RG, and Sheehan DM. “The estrogen receptor relative binding affinities of 188 natural and xenochemicals: Structural diversity of ligands.” Toxicol Sci 2000; 54:138-153.

Box KJ, Volgyi G, Baka E, Stuart M, Takacs-Novak K, Comer JE. "Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution - a validation study". J Pharm Sci 2006; 95:1298-1307.

Box KJ and Comer JEA. “Using Measured pKa, LogP, and Solubility to Investigate Supersaturation and Predict BCS Class.” Curr Drug Metab 2008; 9:869-878.

Box K, Comer JE, Gravestock T and Stuart M. "New ideas about the solubility of drugs." Chem Biodivers 2009; 6:1767-1788.

Boyd SA, Fung AKL, Baker WR, Mantei RA, Stein HH, Cohen J, Barlow JL, Klinghofer V, Wessale JL. Nonpeptide Renin Inhibitors with Good Intraduodenal Bioavailability and Efficacy in Dog. J Med Chem 1994;37(19):2991–3007.

Branham WS, Dial SL, Moland CL, Hass BS, Blair RM, Fang H, Shi L, Tong W, Perkins RG, and Sheehan DM. “Binding of phytoestrogens and mycoestrogens to the rat uterine estrogen receptor.” J Nutr 2002; 134:658-664.

Brenk, R, Schipani, A, James, D, Krasowski, A, Gilbert, I, Frearson, J and Wyatt, P, “Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases”, ChemMedChem 2008, 3:435-444.

Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 3rd Edition. Lippincott, Williams & Wilkins; Baltimore, MD (1990).

Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea T, Cruciani G. “A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields.” J Med Chem 2011; 54:1740-1751.

Brown HS, Griffin M, Houston JB. “Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.” Drug Metab Dispos 2007; 35:293-301.

Bu H-Z. "A Literature Review of Enzyme Kinetic Parameters for CYP3A4-Mediated Metabolic Reactions of 113 Drugs in Human Liver Microsomes: Structure-Kinetics Relationship Assessment." Curr Drug Metab 2006; 7:231-249.

Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 2010; 99:4940-54.

Cai Y, Yang H, Li W, Liu G, Lee PW, Tang Y. "Computational Prediction of Site of Metabolism for UGT-Catalyzed Reactions." J Chem Inf Model 2019, 59:1085–1095.

Caldeira TG, Saúde-Guimarães DA, González-Álvarez I, Bermejo M, de Souza J. “Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination.” Daru. 2021;29(1):195-203. doi:10.1007/s40199-021-00397-6

Chang C-C, Lin C-J. LIBSVM : a library for support vector machines. ACM Trans Intel Sys Tech 2011, 2:27:1-27.

Charman WN, Porter CJ, Mithani S, Dressman JB. "Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH". J Pharm Sci 1997; 86:269-282.

Chattaraj PK, Sarkar U, Roy DR. "Electrophilicity Index." Chem Rev 2006; 106:2065–2091 (DOI: 10.1021/cr040109f).

Chatzopoulou M, Emer E, Lecci C, Rowley JA, Casagrande A-S, Moir L, Squire SE, Davies SG, Harriman S, Wynne GM, Wilson FX, Davies KE, Russell AJ. Decreasing HepG2 Cytotoxicity by Lowering the Lipophilicity of Benzo[d]oxazolephosphinate Ester Utrophin Modulators. ACS Med Chem Lett 2020;11(12):2421–2427.

Chaves J, Barroso JM, Bultinck P, Carbó-Dorca R. "Toward an Alternative Hardness Kernel Matrix Structure in the Electronegativity Equalization Method (EEM)." J Chem Inf Model 2006; 46:1657–1665 (DOI: 10.1021/ci050505e).

Chen L, Li Y, Zhao Q, Peng H, Hou T "ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques" Mol Pharm . 2011; 8(3):889-900

Chen T, Guestrin C. "XGBoost: A Scalable Tree Boosting System." In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, California, USA; 2016.

Cheng F, Ikenaga Y, Zhou Y, Yu Y, Li W, Shen J, Du Z, Chen L, Xu C, Liu G, Lee PW, Tang Y. "In silico assessment of chemical biodegradability." J Chem Inf Model 2012; 52:655-669.

Cheng Y-C, Prusoff WH. “Relationship between the inhibition constant (Kᵢ) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction.” Biochem Pharmacol. 1973, 22(23):3099-3108.

Chiang Y, Whipple EB. “The Protonation of Pyrroles.” J Am Chem Soc 1963; 85:2763-2767.

Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. “Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells.” Pharm Res. 2003;20(5):749-756. doi:10.1023/A:1023481418576.

Clark RD. "DPRESS: Localizing estimates of predictive uncertainty." J Cheminfo 2009; 1:11.

Clark RD, Liang W, Lee AC, Lawless MS, Fraczkiewicz R, Waldman M. "Using beta binomials to estimate classification uncertainty for ensemble models." J Cheminfo 2014, 6:34.

Cooper M, Llinas A, Hansen P, Caffrey M, Ray A, Sjödin S, Shamovsky I, Wada H, Jellesmark Jensen T, Sivars U, Hultin L, Andersson U, Lundqvist S, Gedda K, Jinton L, Krutrök N, Lewis R, Jansson P, Gardelli C. Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists. J Med Chem 2020;63(17):9705–9730.

Cowley PM, Baker J, Buchanan KI, Carlyle I, Clark JK, Clarkson TR, Deehan M, Edwards D, Kiyoi Y, Martin I, Osbourn D, Walker G, Ward N, Wishart G. Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists. Bioorganic & Medicinal Chemistry Letters 2011;21(7):2034–2039.

Cristianini N, Taylor JS. An Introduction to Support Vector Machines: And Other Kernel-Based Learning Methods. Cambridge University Press, New York, NY, USA. (2001).

Crivori P, Cruciani G, Carrupt PA, Testa B. “Predicting Blood-Brain Barrier Permeation from Three-Dimensional Molecular Structure.” J Med Chem 2000; 43:2204-2216.

Cruciani G, Milani N, Benedetti P, Lepri S, Cerarini L, Baroni M, Spyrakis F, Tortorella S, Mosconi E, and Goracci L. "From experiments to a fast easy-to-use computational methodology to predict human aldehyde oxidase selectivity and metabolic reactions." J Med Chem 2018, 61:360-371.

Dai WG, Dong LC, Shi X, Nguyen J, Evans J, Xu Y, Creasey AA. "Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME)". J Pharm Sci 2007; 96:2957-2969.

Desai, M.A., C.V. Nicholas, and P. Vadgama, Electrochemical determination of the permeability of porcine mucus to model solute compounds. J Pharm Pharmacol, 1991. 43(2): p. 124-7.

Desai, M.A. and P. Vadgama, Estimation of effective diffusion coefficients of model solutes through gastric mucus: assessment of a diffusion chamber technique based on spectrophotometric analysis. Analyst, 1991. 116(11): p. 1113-6.

Diamond S, Boer J, Maduskuie TP Jr., Falahatpisheh N, Li Y, Yeleswaram S. "Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications." Drug Metab Dispos 2010 38:1277-1285.

Dalby A, Nourse JG, Hounshell WD, Gushurst AKI, Grier DL, Leland BA, Laufer J. “Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited.” J Chem Inf Comput Sci 1992; 32:244-255.

Dearden JC, Netzeva TI, Bibby R. "A Comparison of Commercially Available Software for the Prediction of Partition Coefficient." In: EuroQSAR 2002: Designing Drugs and Crop Protectants: Processes, Problems and Solutions, Bournemouth, UK (2003); pp. 168-169.

Dearden JC. "In silico prediction of aqueous solubility." Expert Opin Drug Discov 2006; 1:31-52.

De Bruyn T, Van Westen GJP, IJzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP. "Structure-based identification of OATP1B1/3 inhibitors" Mol Pharmacol. 2013. 83(6):1257-1267.

Degorce SL, Barlaam B, Cadogan E, Dishington A, Ducray R, Glossop SC, Hassall LA, Lach F, Lau A, McGuire TM, Nowak T, Ouvry G, Pike KG, Thomason AG. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. J Med Chem 2016;59(13):6281–6292.

DeNinno MP et al. "Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatent of diabetes." Bioorg Med Chem Lett 2012, 22:5721-5726.

Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, Cox BF, Gintant GA. “The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.” J Pharm Tox Meth 2004; 50:187-199.

DIDB database, https://didb.druginteractionsolutions.org/, accessed 26 Jun 2024.

Didziapetris R, Japertas P, Avdeef A, Petrauskas A. “Classification Analysis of P-Glycoprotein Substrate Specificity.” J Drug Target 2003; 11:391-406.

Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. "Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs." J Pharmacol Exp Ther 2002; 303:1029–1037.

Dimitrov S, Dimitrova N, Parkerton T, Comber M, Bonnell M, Mekenyan O. “Base-line model for identifying the bioaccumulation potential of chemicals.” SAR QSAR Environ Res 2005; 16, 531–554.

Djoumbou-Feunang Y, Fiamoncini J, Gil-de-la-Fuente A, Greiner R, Manach C, Wishart DS. BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification. J Cheminform. 2019 ;11:2.

Durant JL, Leland BA, Henry DR, Nourse JG. "Reoptimization of MDL Keys for Use in Drug Discovery." J. Chem. Inf. Comp. Sci. 2002; 42:1273-1280.

Dressman JB, Reppas C. "In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs." Eur J Pharm Sci 2000; 11(S2):S73-S80.

Ehrnebo M, Nilsson SO, Boréus LO. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J Pharmacokinet Biopharm 1979, 7:429-51.

Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. “Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding.” Xenobiotica 2009; 39:227-235.

Enoch SJ, Roberts DW, Cronin MTD. “Mechanistic Category Formation for the Prediction of Respiratory Sensitization.” Chem Res Toxicol 2010; 23:1547-1555.

Erić S, Kalinić M, Ilić K, Zloh M. “Computational classification models for predicting the interaction of drugs with P-glycoprotein and Breast Cancer Resistance Protein.” SAR QSAR Environ Res 2014; 25: 939-966.

Ertl P, Rohde B, Selzer P. “Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties.” J Med Chem 2000; 43:3714-3717.

Ertl P, Schuffenhauer A. “Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions.” J Cheminfo 2009; 1:8; see the corresponding rdkit and github pages for subsequent modifications.

EURAS Bioconcentration Factor (BCF) Gold Standard Database; 2008. http://ambit.sourceforge.net/euras/.

Fan R-E, Chen P-H, Lin C-J. "LIBSVM : a library for support vector machines." ACM Trans Intel Sys Tech 2011; 2:27:1-27.

Fang C, Wang Y, Grater R, Kapadnis S, Black C, Trapa P, Sciabola S. Prospective Validation of Machine Learning Algorithms for Absorption, Distribution, Metabolism, and Excretion Prediction: An Industrial Perspective. J Chem Inf Model 2023;63(11):3263–3274.

Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W, Hass BS, Xie Q, Dial SL, Moland CL, and Sheehan DM. “Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens.” Chem Res Tox 2001; 14:280-294.

Fang H, Tong W, Branham WS, Moland CL, Dial SL, Hong H, Xie Q, Perkins R, Owens W, Sheehan DM. “Study of 202 Natural, Synthetic, and Environmental Chemicals for Binding to the Androgen Receptor.” Chem Res Toxicol 2003; 16:1338-1358.

Feng Q, De Chavez D, Kihlberg J, Poongavanam V. A membrane permeability database for nonpeptidic macrocycles. Sci Data. 2025;12(1):10. doi:10.1038/s41597-024-04302-z.

Ferreira MA, Azevedo H, Mascarello A, Segretti ND, Russo E, Russo V, Guimarães CRW. Discovery of ACH-000143 : A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats. J Med Chem 2021;64(4):1904–1929.

Finkelmann AR, Goldmann D, Schneider G, Göller AH. MetScore: Site of Metabolism Prediction Beyond Cytochrome P450 Enzymes. ChemMedChem. 2018; 13:2281-2289

Fletcher R. Practical Methods of Optimization: Volume 1, Unconstrained Optimization. John Wiley & Sons (1980).

Fournier J-F, Bhurruth-Alcor Y, Musicki B, Aubert J, Aurelly M, Bouix-Peter C, Bouquet K, Chantalat L, Delorme M, Drean B, Duvert G, Fleury-Bregeot N, Gauthier B, Grisendi K, Harris CS, Hennequin LF, Isabet T, Joly F, Lafitte G, Millois C, Morgentin R, Pascau J, Piwnica D, Rival Y, Soulet C, Thoreau É, Tomas L. Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma. Bioorganic & Medicinal Chemistry Letters 2018;28(17):2985–2992.

Fraczkiewicz R. "In silico Prediction of Ionization." In Reference Module in Chemistry, Molecular Sciences and Chemical Engineering [Online], Reedijk J, Ed.; Elsevier, 2013; Vol. 5, Chapter 5.25.

Fraczkiewicz R, Lobell M, Göller AH, Krenz U, Schoenneis R, Clark RD, Hillisch A. "Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology To Improve in Silico pKa Prediction." J Chem Inf Model 2015; 55:389–397.

Fraczkiewicz R, Quoc Nguyen H, Wu N, Kausch-Busies N, Grimbs S, Sommer K, ter Laak A, Günther J, Wagner B, Reutlinger M. "Best of both worlds: An expansion of the state of the art pKa model with data from three industrial partners." Mol Inf 2024; 43:e202400088.

Fraczkiewicz R, Waldman M. "pK50─A Rigorous Indicator of Individual Functional Group Acidity/Basicity in Multiprotic Compounds." J Chem Inf Model 2023; 63:3198.

Fraczkiewicz R. "Can an Amine Be a Weaker and a Stronger Base at the Same Time? Curious Cases of Chameleonic Ionization." ACS Phys Chem Au 2023; 3:512-514.

Fraczkiewicz R, Waldman M. "Modeling Carbon Basicity." Mol Inf 2025; 44:e202400296.

Fraczkiewicz, R. “What, This ‘Base’ Is Not a Base? Common Misconceptions about Aqueous Ionization That May Hinder Drug Discovery and Development.” J Med Chem 2025, 68:21003-21011.

Fu XC, Liang WQ. “A Simple Model for the Prediction of Corneal Permeability.” Int J Pharm 2002; 232:193-197.

Fujino H, Saito T, Tsunenary Y, Kojima J, Sakaeda T. "Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors." Xenobiotica 2004, 34:961–971.

Gabbert S, Weikard H-P. "Sequential Testing of Chemicals When Costs Matter: A Value of Information Approach." Human Eco Risk Assess 2013; 19:1067-1088

Gobeau N, Stringer R, De Buck S, Tuntland T, Faller B "Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery" Pharm Res 2016; 33:2126-39

Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. "Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs." Pharm Res 1998; 15:698-705.

Garcia Jimenez D, Vallaro M, Rossi Sebastiano M, et al. Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs. J Med Chem. 2023;66(15):10681-10693. doi:10.1021/acs.jmedchem.3c00823

Gardner I, Xu M, Han C, Wang Y, Jiao X, Jamei M, Khalidi H, Kilford P, Neuhoff S, Southall R,

Turner DB, Musther H, Jones B, Taylor S. "Non-Specific Binding of Compounds in in Vitro

Metabolism Assays: A Comparison of Microsomal and Hepatocyte Binding in Different Species

and an Assessment of the Accuracy of Prediction Models." Xenobiotica 2022; 52:943–956.

Gatehouse D et al. "Recommendations for the performance of bacterial mutation assays." Mutation Res 1994; 312:217-233.

Genheden S, Thakkar A, Chadimová V, Reymond JL, Engkvist O, Bjerrum E. AiZynthFinder: a fast, robust and flexible open-source software for retrosynthetic planning. J Cheminform. 2020;12(1):70. doi:10.1186/s13321-020-00472-1

Gerberick GF, Ryan CA, Kern PS, Schlatter H, Dearman RJ, Kimber I, Patlewicz GY, Basketter DA. “Compilation of historical local lymph node data for evaluation of skin sensitization alternative methods.” Dermatitis 2005; 16:157-202.

Gertz M, Kilford PJ, Houston JB, Galetin A. “Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations.” Drug Metab Dispos 2008; 36:535-542.

Ghanooni M, Mattiston DR, Zhang YP, Macina OT, Rosenkranz HS, Klopman G. “Structural determinants associated with risk of human developmental toxicity.” Am J Obstet Gynecol 1997; 176:799–806.

Gill KL, Houston JB, Galetin A. Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin. Drug Metab Dispos 2012;40(4):825–835.

Glen WG, Dunn WJ, Scott DR. “Principal Component Analysis and Partial Least Squares Regression.” Tetrahedron Comput. Methodol 1989; 2:349.

Goetz GH, Philippe L, Shapiro MJ. EPSA: “A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.” ACS Med Chem Lett. 2014;5(10):1167-1172. doi:10.1021/ml500239m

Goetz GH, Shalaeva M, Caron G, Ermondi G, Philippe L. “Relationship between Passive Permeability and Molecular Polarity Using Block Relevance Analysis.” Mol Pharmaceutics. 2017;14(2):386-393. doi:10.1021/acs.molpharmaceut.6b00724

Gold LS et al. “The Carcinogenic Potency Project.” https://toxnet.nlm.nih.gov/cpdb/

Gold LS, Manley NB, Slone TH and Rohrbach L. “Supplement to the Carcinogenic Potency Database (CPDB): Results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996.” Environ Health Perspect 1999; 107(Suppl. 4): 527-600.

Golub GH, van Loan CF. Matrix Computations. The John Hopkins University Press, Baltimore and London (1989).

Gomtsyan A. et al, Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists. J Med Chem, 2016; 59:4926–4947.

Gorodkin J. “Comparing two K-category assignments by a K-category correlation coefficient.” Comput Biol Chem 2004; 28:367-374.

Goyal S, Patel KV, Nagare Y, Raykar DB, Raikar SS, Dolas A, Khurana P, Cyriac R, Sarak S, Gangar M, Agarwal AK, Kulkarni A. Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D. Bioorganic & Medicinal Chemistry 2021;29115879.

Graham C, Rosenkranz HS, Karol MH. “Structure-Activity Model of Chemicals That Cause Human Respiratory Sensitization.” Reg Toxicol Pharmacol 1997; 26:296-306.

Grant JA, Pickup BT. "A Gaussian Description of Molecular Shape." J Phys Chem 1995; 99: 3503-3510.

Guan C, Yang Y, Tian D, et al. “Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans.” Eur J Drug Metab Pharmacokinet. 2022;47(5):639-652. doi:10.1007/s13318-022-00780-x

Guengerich FP. “Cytochrome P450 and Chemical Toxicology.” Chem Res Toxicol 2008; 21:70-83.

Gujjar R et al. “Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice.” J Med Chem 2011; 54:3935–3949.

 Halgren TA. "Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94." J Comp Chem 1996; 17:490-519.

Hall L, Kier L. "The Electrotopological State: Structure Information at the Atomic Level for Molecular Graphs." J Chem Inf Comput Sci 1991; 31:76-82.

Hall L, Mohney B, Kier L. "Electrotopological State Indices for Atom Types: A Novel Combination of Electronic, Topological, and Valence State Information." J Chem Inf Comput Sci 1995; 35:1039-1045.

Hansen K et al. "Benchmark Data Set for in Silico Prediction of Ames Mutagenicity" J Chem Inf Model 2009, 49:2077–2081.

Hallifax D, Houston JB. “Binding of drugs to hepatic microsomes: Comment and assessment of current prediction methodology with recommendation for improvement.” Drug Metab Dispos 2006; 34:724-726.

Hallifax D, Houston JB. “Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction” Drug Metab Dispos 2007; 35:1325-1332.

Hamelink JL. “Current bioconcentration test methods and theory.” In: Aquatic Toxicology and Hazard Evaluation. Eds: Mayer FL, Hamelink JL. ASTM STP, West Conshohocken, PA (1977).

Hao J, Beck JP, Schaus JM, Krushinski JH, Chen Q, Beadle CD, Vidal P, Reinhard MR, Dressman BA, Massey SM, Boulet SL, Cohen MP, Watson BM, Tupper D, Gardinier KM, Myers J, Johansson AM, Richardson J, Richards DS, Hembre EJ, Remick DM, Coates DA, Bhardwaj RM, Diseroad BA, Bender D, Stephenson G, Wolfangel CD, Diaz N, Getman BG, Wang X, Heinz BA, Cramer JW, Zhou X, Maren DL, Falcone JF, Wright RA, Mitchell SN, Carter G, Yang CR, Bruns RF, Svensson KA. Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1 S ,3 R )-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1 H )-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor. J Med Chem 2019;62(19):8711–8732.

Hansch C et al. Exploring QSAR: Hydrophobic, Electronic, and Steric Constraints. ACS Publications (1995).

Hayduk W, Laudie H. “Prediction of Diffusion Coefficients for Nonelectrolytes in Dilute Aqueous Solutions” American Institute of Chemical Engineers J. 1974; 20:611.

Hazai E, Hazai I, Ragueneau-Majlessi I, Chung SP, Bikadi Z, Mao Q. "Predicting substrates of the human breast cancer resistance protein using a support vector machine method." BMC Bioinformatics. 2013, 15:14:130

Heald R, Bowman KK, Bryan MC, Burdick D, Chan B, Chan E, Chen Y, Clausen S, Dominguez-Fernandez B, Eigenbrot C, Elliott R, Hanan EJ, Jackson P, Knight J, La H, Lainchbury M, Malek S, Mann S, Merchant M, Mortara K, Purkey H, Schaefer G, Schmidt S, Seward E, Sideris S, Shao L, Wang S, Yeap K, Yen I, Yu C, Heffron TP. Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 2015;58(22):8877–8895.

Hendrickx R, Johansson JG, Lohmann C, Jenvert R, Blomgren A, Börjesson L, Gustavsson L. "Identification of Novel Substrates and Structure–Activity Relationship of Cellular Uptake Mediated by Human Organic Cation Transporters 1 and 2." J Med Chem. 2013, 56:7232-7242

Hennemann M, Friedl A, Lobell M, Keldenich J, Hillisch A, Clark T, and Göller AH. “CypScore: Quantitative Prediction of Reactivity toward Cytochromes P450 Based on Semiempirical Molecular Orbital Theory.” Chem Med Chem 2009; 4:657-669.

Hinman RL, Whipple EB. “The Protonation of Indoles: Position of Protonation.” J Am Chem Soc 1962; 84:2534-2539.

Hirano M, Maeda K, Shitara Y, & Sugiyama Y. "Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans." J Pharm Exp Ther. 2004, 311:139–146.

Hong F-T, Norman MH, Ashton KS, Bartberger MD, Chen J, Chmait S, Cupples R, Fotsch C, Jordan SR, Lloyd DJ, Sivits G, Tadesse S, Hale C, St. Jean DJ. Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding Pocket. J Med Chem 2014;57(14):5949–5964.

Hong HK, Lee BH, Park MH, Lee SH, Chu D, Kim WJ, Choe H, Hee Choi B, Jo SH. "Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration." Eur J Pharmacol 2013, 702:165-173.

Honma M, Kitazawa A, Cayley A, Williams RV, Barber C, Hanser T, Saiakhov R, Chakravarti S, Myatt GJ, Cross KP, Benfenati E, Raitano G, Mekenyan O, Petkov P, Bossa C, Benigni R, Battistelli CL, Giuliani A, Tcheremenskaia O, DeMeo C, Norinder U0, Koga H, Jose C, Jeliazkova N, Kochev N, Paskaleva V, Yang C, Daga PR, Clark RD, Rathman J. "Improvement of quantitative structure-activity relationship (QSAR) tools for predicting Ames mutagenicity: outcomes of the Ames/QSAR International Challenge Project." Mutagenesis. 2019, 34:3-16

Houston JB, Kenworthy KE. "In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model." Drug Metab Dispos 2000, 28:246-254.

Huttunen KM, Raunio H, Rautio J. “Prodrugs - from Serendipity to Rational Design.” Pharmacol Rev 2011, 63:750-771.

Hwang C-L, Yoon K. Multiple Attribute Decision Making. Berlin, Heidelberg: Springer Berlin Heidelberg.;

Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. "In vitro and in vivo glucuronidation of midazolam in humans." Brit J Clin Pharmacol 2009; 67:445-454.

Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, Schäfer C, Eichelbaum M, Fromm MF. "Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux." Clin Pharmacokin 2007, 46:777–785.

Ikeda K, Yoshisue K, and Mastsushima E. “Bioactivation of Tegafur to 5-Fluorouracil is Catalyzed by Cytochrome P450 2A6 in Human Liver Microsomes in Vitro.” Clin Cancer Res 2000; 6:4409-4415.

Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. “Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences.” Xenobiotica 2006; 36:499.

Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE and Grove JR. “MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability Screening.” J Pharm Sci 1999; 88:28-33.

Isik M, Rustenburg AS, Rizzi A, Gunner MR, Mobley DL, Chodera JD. "Overview of the SAMPL6 pKa challenge: evaluating small molecule microscopic and macroscopic pKa predictions." J. Comput.-Aided Mol. Des. 2021; 35(2):131-166. DOI: 10.1007/s10822-020-00362-6.

Jantratid E, Janssen N, Reppas C, Dressman J. “Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update.” Pharm Res 2008; 25:1663.

Jones HM, Parrott N, Ohlenbusch G, Lave T. "Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling". Clin Pharmacokinet 2006; 45:1213-1226.

Jones RS, Leung C, Chang JH, Brown S, Liu N, Yan Z, Kenny JR, Broccatelli F. Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs. Drug Metab Dispos 2022;50(8):1053–1063.

Judson, R ToxValDB v9.4. U.S. Environmental Protection Agency, Washington, DC, 2023. https://doi.org/10.23645/epacomptox.20394501.

Juntunen J, Majumdar S, Sloan K. “The effect of water solubility of solutes on their flux through human skin in vitro: A prodrug database integrated into the extended Flynn database.” Int J Pharmaceutics 2008; 351:92-103.

Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. "Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions." J Med Chem 2012; 55:4740-4763.

Karlgren M, Ahlin G, Bergstrom CAS, Svensson R, Palm J, Artursson P. “In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions.” Pharm Res 2012; 29:411-426.

Kai H, Horiguchi T, Kameyma T, Onodera N, Itoh N, Fujii Y, Ichihashi Y, Hirai K, Shintani T, Nakamura K, Minami K, Kasai E, Yoneda S, Murakami Y, Ogawa H, Sekimoto R, Shinohara S, Yoshida O, Kurose N. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2021;52128384.

Kaivosaari S, Finel M, Koskinen, M. "N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases." Xenobiotica 2011, 41:652-669.

Kempf DJ, Sham HL, Marsh KC, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kati WM, Ruiz L, Zhao C, Fino L, Patterson J, Molla A, Plattner JJ, Norbeck DW. Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy. J Med Chem 1998;41(4):602–617.

Khanvilkar, K., Drug transfer through mucus. Advanced Drug Delivery Reviews, 2001. 48(2-3): p. 173-193.

Kido Y, Matsson P, Giacomini KM. “Profiling of a prescription drug library for potential renal drug-drug interaction by OCT2.” J. Med Chem. 2011; 54:4548-4558.

Kidron K, Vellonen K, Amo EM, Tissari A, Urtti A. “ Prediction of the Corneal Permeability of Drug-Like Compounds.” Pharm Res 2010; 27:1398-1407.

Kilford PJ, Gertz M, Houston JB, Galetin A. “Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data” Drug Metab Dispos 2008; 36:1194-1197.

Kohonen T. “Self-organized formation of topologically correct feature maps.” Biol Cybernetics 1982; 43:59 – 69.

Kohonen T. Self-organization and associative memory. Springer Verlag (1984).

Koovits PJ, Dessoy MA, Matheeussen A, Maes L, Caljon G, Mowbray CE, Kratz JM, Dias LC. Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic & Medicinal Chemistry Letters 2020;30(1):126779.

Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. "Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine." J Pharm Pharmacol 2004; 56:43-51.

Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KLR. “Risk Factors for Development of Cholestatic Drug-Induced Liver Injury: Inhibition of Hepatic Basolateral Bile Acid Transporters Multidrug Resistance-Associated Proteins 3 and 4.” Drug Metab Dispos 2014, 42:665-674.

Kruhlak NL, Benz RD, Zhou H, Colatsky TJ. "(Q) SAR modeling and safety assessment in regulatory review." Clin Pharm Ther 2011; 91:529-534.

Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 1993;36(16):2343–2349.

Kukolja S, Wright WE, Quay JF, Pfeil-Doyle J, Draheim SE, Eudaly JA, Johnson RJ, Ott JL, Counter FT. Oral absorption of cephalosporin antibiotics. 1. Synthesis, biological properties and oral bioavailability of 7-arylacetamido-3-chloro cephalosporins in animals. J Med Chem 1988;31(10):1987–1993.

Kung P-P, Bingham P, Brooun A, Collins M, Deng Y-L, Dinh D, Fan C, Gajiwala KS, Grantner R, Gukasyan HJ, Hu W, Huang B, Kania R, Kephart SE, Krivacic C, Kumpf RA, Khamphavong P, Kraus M, Liu W, Maegley KA, Nguyen L, Ren S, Richter D, Rollins RA, Sach N, Sharma S, Sherrill J, Spangler J, Stewart AE, Sutton S, Uryu S, Verhelle D, Wang H, Wang S, Wythes M, Xin S, Yamazaki S, Zhu H, Zhu J, Zehnder L, Edwards M. Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate ( R )-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2 H )-one (PF-06821497). J Med Chem 2018;61(3):650–665.

Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y. "In silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters." Drug Metab Dispos 2010; 38:1362-1370.

Lafforgue G , Arellano C, Vachoux C, Woodley J, Philibert C, Dupouy V, Bousquet-Mélou A, Gandia P, Houin G. "Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter." Fundam Clin Pharmacol 2008, 22:189-201.

Lai Y, "P-glycoprotein (P-gp/MDR1)/ABCB1", Editor(s): Yurong Lai, In Woodhead Publishing Series in Biomedicine, Transporters in Drug Discovery and Development, Woodhead Publishing, 2013, Pp:147-259

Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G, Kopecky DJ, Liu L, Lopez P, Low JD, Ma V, Minatti AE, Nguyen TT, Nishimura N, Pickrell AJ, Reed AB, Shin Y, Siegmund AC, Tamayo NA, Tegley CM, Walton MC, Wang H-L, Wurz RP, Xue M, Yang KC, Achanta P, Bartberger MD, Canon J, Hollis LS, McCarter JD, Mohr C, Rex K, Saiki AY, San Miguel T, Volak LP, Wang KH, Whittington DA, Zech SG, Lipford JR, Cee VJ. Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors. J Med Chem 2020;63(1):52–65.

Larhed AW, Artursson P, Gråsjö J, Björk E. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci. 1997 Jun;86(6):660-5. doi: 10.1021/js960503w. PMID: 9188047.

Larhed, A.W., P. Artursson, and E. Bjork, The influence of intestinal mucus components on the diffusion of drugs. Pharm Res, 1998. 15(1): p. 66-71.

Li Q, Chu DTW, Claiborne A, Cooper CS, Lee CM, Raye K, Berst KB, Donner P, Wang W, Hasvold L, Fung A, Ma Z, Tufano M, Flamm R, Shen LL, Baranowski J, Nilius A, Alder J, Meulbroek J, Marsh K, Crowell D, Hui Y, Seif L, Melcher LM, Henry R, Spanton S, Faghih R, Klein LL, Tanaka SK, Plattner JJ. Synthesis and Structure−Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents. J Med Chem 1996;39(16):3070–3088.

Li L, Whitney-Pickett C, Umland JP, et al. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci. 2011;100(11):4974-4985. doi:10.1002/jps.22674

Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. “Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man.” Pharm Res 1992; 10:1243–51.

Lennernas H. “Human Intestinal Permeability”, J Pharm Sci 1998; 87:403-410.

Lennernäs H. “Intestinal permeability and its relevance for absorption and elimination.” Xenobiotica. 2007 Oct-Nov;37(10-11):1015-51.

Lewell XQ, Judd DB, Watson SP, Hann MM. “RECAP – Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry.” J Chem Inf Comput Sci 1998; 38: 511-522.

Lewinsky RH, Smith PA and Mackenzie PI. “Glucuronidation of bioflavonoids by human UGT1A10: Structure-function Relationships.” Xenobiotica 2005; 35: 117-129.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL. “The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer.” J Med Chem 2012;55(14):6523–6540.

Li H, Sun J, Sui X, Yan Z, Sun Y, Liu X, Wang Y, He Z. “Structure-Based prediction of the nonspecific binding of drugs to hepatic microsomes.” The AAPS Journal 2009; 11:364-370.

Li J, Yanagisawa K, Sugita M, Fujie T, Ohue M, Akiyama Y. CycPeptMPDB: A Comprehensive Database of Membrane Permeability of Cyclic Peptides. J Chem Inf Model. 2023;63(7):2240-2250. doi:10.1021/acs.jcim.2c01573.

Li Y, Liu J, Pan D, Hopfinger AJ. “A Study of the Relationship between Cornea Permeability and Eye irritation Using Membrane-Interaction QSAR Analysis.” Toxicol Sci 2005; 88:434-446.

Li J, Gramatica P. “Classification and Virtual Screening of Androgen Receptor Antagonists.” J Chem Inf Model 2010; 50: 861-874.

Li X, Payne DT, Ampolu B, Bland N, Brown JT, Dutton MJ, Fitton CA, Gulliver A, Hale L, Hamza D, Jones G, Lane R, Leach AG, Male L, Merisor EG, Morton MJ, Quy AS, Roberts R, Scarll R, Schulz-Utermoehl T, Stankovic T, Stevenson B, Fossey JS, Agathanggelou A. Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia. Med Chem Commun 2019;10(8):1379–1390.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. “Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings.” Adv Drug Delivery Rev 1997; 23:3-25.

Liu J, Xiong L, Pei J, Luo J, Zhang H, and Yu W, "Group-based Skyline for Pareto Optimal Groups," IEEE Transactions on Knowledge and Data Engineering, 2019, doi: 10.1109/TKDE.2019.2960347

Llinàs A, Glen R, Goodman J. “Solubility Challenge: Can You Predict Solubilities of 32 Molecules Using a Database of 100 Reliable Measurements?” J Chem Inf Model 2008; 48:1289-1303.

Lloyd SP. “Least squares quantization in PCM.” IEEE Trans Inf Theory 1982; 28:129-137.

Lombardo F and Jing Y. “In Silico Prediction of Volume of Distribution in Humans. Extensive Data Set and the Exploration of Linear and Nonlinear Methods Coupled with Molecular Interaction Fields Descriptors”. J. Chem. Inf. Model. 2016, 56:2042-2052.

Lowe R, Glen R, Mitchell JBO. “Predicting Phospholipidosis Using Machine Learning.” Mol Pharm 2010; 7:1708-1714.

Lukacova V, Parrott N, Lavé T, Fraczkiewicz G, Bolger MB, Woltosz WS. "General approach to calculation of tissue:plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling." AAPS Annual Meeting Poster Presentation; 2008 Nov 16; Atlanta, GA, USA.

Lundberg SM, Lee SI. "A unified approach to interpreting model predictions." Proceedings of the 31st International Conference on Neural Information Processing Systems 2017; 4768-4777. Long Beach, California, USA.

Lundberg SM, Erion GG, Lee SI. "Consistent Individualized Feature Attribution for Tree Ensembles." arXiv 2019; 1802.03888: https://arxiv.org/abs/1802.03888.

Macsari I, Besidski Y, Csjernyik G, Nilsson LI, Sandberg L, Yngve U, Åhlin K, Bueters T, Eriksson AB, Lund P-E, Venyike E, Oerther S, Hygge Blakeman K, Luo L, Arvidsson PI. 3-Oxoisoindoline-1-carboxamides: Potent, State-Dependent Blockers of Voltage-Gated Sodium Channel Na V 1.7 with Efficacy in Rat Pain Models. J Med Chem 2012;55(15):6866–6880.

Maggiora GM. “On outliers and activity cliffs – Why QSAR often disappoints.” J Chem Inf Model 2006; 46:1535-1535.

Majumdar S, Thomas J, Wasdo S, Sloan KB. “The effect of water solubility of solutes on their flux through human skin in vitro” Int J Pharm 2007; 329:25-36.

Mallinger A, Schiemann K, Rink C, Sejberg J, Honey MA, Czodrowski P, Stubbs M, Poeschke O, Busch M, Schneider R, Schwarz D, Musil D, Burke R, Urbahns K, Workman P, Wienke D, Clarke PA, Raynaud FI, Eccles SA, Esdar C, Rohdich F, Blagg J. 2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. ACS Med Chem Lett 2016;7(6):573–578.

Mallinger A, Schiemann K, Rink C, Stieber F, Calderini M, Crumpler S, Stubbs M, Adeniji-Popoola O, Poeschke O, Busch M, Czodrowski P, Musil D, Schwarz D, Ortiz-Ruiz M-J, Schneider R, Thai C, Valenti M, de Haven Brandon A, Burke R, Workman P, Dale T, Wienke D, Clarke PA, Esdar C, Raynaud FI, Eccles SA, Rohdich F, Blagg J. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. J Med Chem 2016;59(3):1078–1101.

Manchester J, Walkup G, Rivin O, You Z. “Evaluation of pKa Estimation Methods on 211 Druglike Compounds.” J Chem Inf Model 2010; 50:565-571.

Mannhold R, Poda GI, Ostermann C, Tetko IV. “Calculation of Molecular Lipophilicity: State-of-the-Art and Comparison of Log P Methods on More Than 96,000 Compounds.” J Pharm Sci 2009; 98:861-893.

Mao Q, Unadkat JD. "Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update." AAPS J. 2015, 17:65-68.

Marosi A, Kovacs Z, Beni S, Kokosi J, Noszal B. ”Triprotic acid-base microequilibria and pharmacokinetic sequelae of cetirizine.” Eur J Pharm Sci 2009; 37:321-328.

Mata G, Miles DH, Drew SL, Fournier J, Lawson KV, Mailyan AK, Sharif EU, Yan X, Beatty JW, Banuelos J, Chen J, Ginn E, Chen A, Gerrick KY, Pham AT, Wong K, Soni D, Dhanota P, Shaqfeh SG, Meleza C, Narasappa N, Singh H, Zhao X, Jin L, Schindler U, Walters MJ, Young SW, Walker NP, Leleti MR, Powers JP, Jeffrey JL. Design, Synthesis, and Structure–Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ). J Med Chem 2022;65(2):1418–1444.

Matthews EJ, Kruhlak NL, Benz RD and Contrera JF “Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.” CurrDrug Disco Techn 2004; 1:61-76.

Matthews EJ, Kruhlak NL, Weaver JL, Benz RD and Contrera JF “Assessment of the health effects of chemicals in humans: II. Construction of an Adverse Effects Database for QSAR Modeling.” CurrDrug Disco Tech 2004; 1:243-254.

Maxwell WR, Partington JR. “The dissociation constants of some polybasic acids.” Trans Faraday Soc 1935; 31:922-935.

May RJ, Maier HR, Dandy GC. "Data splitting for artificial neural networks using SOM-based stratified sampling." Neural Networks 2010; 23:283-294.

Mayers RH. Classical and Modern Regression with Applications. Duxbury Press (1989).

Meanwell NA. “Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety.” Chem Res Toxicol 2011; 24:1420–1456.

Mernissi-Arifi K, Schmitt L, Schlewer G, Spiess B. "Complete Resolution of the Microscopic Protonation Equilibria of D-Myo-Inositol 1,2,6-Tris(phosphate) and Related Compounds by ³¹P NMR and Potentiometry." Anal. Chem. 1995; 67:2567-2574.

Meylan WM, Howard PH, Boethling RS. “Improved method for estimating water solubility from Octanol/Water partition coefficient.” Env Tox Chem 1996; 15:100-106.

Michaelides MR, Kluge A, Patane M, Van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R, Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA, Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA. Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. ACS Med Chem Lett 2018;9(1):28–33.

Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. "Estimation of the increase in solubility of drugs as a function of bile salt concentration". Pharm Res 1996; 13:163-167.

Mobley D, Guthrie JP. Journal of Computer-Aided Molecular Design 2014; 28: 711-720.

Moine CE, Privat R, Sirjean B, Jaubert J-N. Journal of Physical and Chemical Reference Data 2017; 46: 033102.

Montanari F, Ecker GF "BCRP Inhibition: from Data Collection to Ligand-Based Modeling" Mol Inform 2014; 33:322-331

Montefiori M, Jørgensen FS, Lars Olsen L. "Aldehyde Oxidase: Reaction Mechanism and Prediction of Site of Metabolism." ACS Omega 2017; 2:4237−4244.

Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn II RT, Afshari CA, Hamadeh HK. "A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development." Tox. Sci, 2013; 136:216-241.

Moriguchi I, Hirono S, Liu Q, Nakagome I, Matsushita Y. “Simple method of calculating Octanol/Water Partition Coefficient.” Chem Pharm Bull 1992; 40:127-130.

Moriguchi I, Hirono S, Nakagome I, Hirano H. “Comparison of reliability of log P values for drugs calculated by several methods.” Chem Pharm Bull 1994; 42:976-978.

Mortelmans K and Ziegler E. "The Ames Salmonella/microsome mutagenicity assay.” Mutation Research 2000; 455:29-60.

Mukherjee G, Gupta PL, Jayaram B. Predicting the binding modes and sites of metabolism of xenobiotics. Mol BioSystems 2015, 11:1914-1924

Murugesan D, Mital A, Kaiser M, Shackleford DM, Morizzi J, Katneni K, Campbell M, Hudson A, Charman SA, Yeates C, Gilbert IH. Discovery and Structure–Activity Relationships of Pyrrolone Antimalarials. J Med Chem 2013;56(7):2975–2990.

Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. “Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.” Drug Metab Dispos 2001; 29:1316-1324.

Newman JH. https://en.wikiquote.org/wiki/John_Henry_Newman; accessed 18 Jan 2016.

Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ, “The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.” Eur J Clin Pharmacol 2006; 62:1003-1009.

Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. "Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data." Pharm Res 1999; 16:1876-1882.

Niemi GJ. “Multivariate Analysis and QSAR: Applications of Principal Components Analysis.” In: Practical Applications of Quantitative Structure-Activity Relationships (QSAR) in Environmental Chemistry and Toxicology. Eds. Karcher W, Devillers J., ECSC, EEC, EAEC: Brussels, (1990); pp. 153-169.

Nioi P, Perry BK, Wang E-J, Gu Y-Z, Snyder RD. “In Vitro Detection of Drug-Induced Phospholipidosis Using Gene Expression and Fluorescent Phospholipid Based Methodologies." Toxicol Sci 2007; 99:162–173.

Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Middekadi VR, Bogaraju N, Ravella SR, Singh P, Birangal SR, Subramanian R, Palacharla RC, Benade V, Muddana N, Jayarajan P. Synthesis, Structure–Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT 4 Receptor Partial Agonists. J Med Chem 2018;61(11):4993–5008.

Noszal B. "Microspeciation of Polypeptides." J. Phys. Chem. 1986; 90:6345-6349.

Obach RS. “Prediction of Human Clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes.” Drug Metab Dispos 1999; 27:1350-1359.

Obach RS. “Metabolism of ezlopitant, a nonpeptidic Substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome p450 isoform identity, and in vitro-in vivo correlation” Drug Metab Dispos 2000; 28:1069-1076.

Obach RS, Lombardo F, Waters NJ, “Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds.” Drug Metab Dispos 2008; 36:1385.

Obach RS, Walker GS, Sharma R, Jenkinson S, Tran TP, Stepan AF. “Lead Diversification at the Nanomole Scale Using Liver Microsomes and Quantitative Nuclear Magnetic Resonance Spectroscopy: Application to Phosphodiesterase 2 Inhibitors.” J Med Chem. 2018;61(8):3626-3640. doi:10.1021/acs.jmedchem.8b00116

Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ-Y, Ramanathan S, Sharma A, León F, Hiranita T, Avery BA, McMahon LR, McCurdy CR. Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids. J Med Chem 2020;63(1):433–439.

Oda S, Fukami T, Yokoi T, Nakajima M. "A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development." Drug Metab Pharmacokinetics 2015; 30:30-51.

Okazaki A, Mano T, Sugano K. "Theoretical dissolution model of poly-disperse drug particles in biorelevant media." J Pharm Sci 2008; 97:1843-1852.

Okumu A, DiMaso M, Lobenberg R. "Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products". Eur J Pharm Biopharm 2009; 72:91-98.

Opricovic S, Tzeng G-H. "Compromise solution by MCDM methods: A comparative analysis of VIKOR and TOPSIS." European Journal of Operational Research 2004;156(2):445–455.

Orogo AM, Choi SS, Minnier BL, Khrulak NL. “Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.” Mol Inf 2012; 31:725-739.

Orozco CC, Atkinson K, Ryu S, et al. “Structural attributes influencing unbound tissue distribution.” European Journal of Medicinal Chemistry. 2020;185:111813. doi:10.1016/j.ejmech.2019.111813

Pagliara A, Carrupt P-A, Caron G, Gaillard P, Testa B. “Lipophilicity Profiles of Ampholytes.” Chem Rev 1997; 97:3385-3340.

Paixão P, Gouveia LF, Morais JA. “Prediction of Drug Distribution within Blood” Eur J Pharm Sci 2009; 36: 544-554.

Paixão P, Gouveia LF, Morais JA. "Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model." Int J Pharm. 2012; 429:84-98 

Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. "Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects". AAPS J 2009; 11:45-53.

Pearce RG, Setzer RW, Strope CL, Sipes NS, and Wambaugh JF. "httk: R Package for High-Throughput Toxicokinetics." J Stat. Software, 2017, 79, 4.

Pedretti A, Villa L, Vistoli G, Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J. Med Chem. 2002; 45:1460-1465

Peinhardt G, Wiese M. "Microionization Constants: Novel Approach for the Determination of the Zwitterionic Equilibrium of Hydroxyphenylalkylamines by Photometric Titration." Int. J. Pharm. 2001; 215:83-89.

Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N. “Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential.” J Chem Inf Model 2007; 47:1196–1205.

Peng J, Lu J, Shen Q, Zheng M, Luo X, Zhu W, Jiang H, Chen K. "In silico site of metabolism prediction for human UGT-catalyzed reactions." Bioinformatics 2014, 30:30-51.

Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernas H, Abrahamsson B. "The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids." Pharm Res 2005; 22:2141-2151.

Petit J, Meurice N, Kaiser C, Maggiora G. “Softening the Rule of Five – where to draw the line?” Bioorg Med Chem 2012; 20:5343-5351.

Polli JW; Wring SA; Humphreys JE; Huang L; Morgan J B; Webster LO; Serabjit-Singh CS. "Rational use of in vitro P-glycoprotein assays in drug discovery." J Pharmacol Exp Ther 2001; 299:620-628.

Poulin P, Haddad S. “Microsome Composition-Based Model as a Mechanistic Tool to Predict Nonspecific Binding of Drugs in Liver Microsomes” J Pharma Sci 2011; 100:4501-17.

Prausnitz MR, Noonan JS. “Permeability of Cornea, Sclera, and Conjunctiva: A Literature Analysis for Drug Delivery to the Eye.” J Pharm Sci 1998; 87:1479-1488.

Przybylak KR, Cronin MTD. “In Silico Studies of the Relationship between Chemical Structure and Drug Induced Phospholipidosis.” Mol Inf 2011; 30:415-429.

Ran Y, Yalkowsky SH. “Prediction of Drug Solubility by the General Solubility Equation (GSE).” J Chem Inf Comput Sci 2001; 41:354-357.

Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. "In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates." Drug Metab Dispos 2006; 34:786–792.

Rautio J, Meanwell NA, Di L, Hageman MJ. "The expanding role of prodrugs in contemporary drug design and development." Nature Rev Drug Disco 2018, 17:559-587.

Reasor MJ, Kacew S. “Drug-Induced Phospholipidosis: Are There Functional Consequences” Exp Biol Med 2001; 226:825–830.

Reid RC, Pransnitz JM, Sherwood TK. The Properties of Gases and Liquids. McGraw Hill Book Co., NY (1977).

Rendic S. “Summary of Information on Human CYP Enzymes: Human P450 Metabolism Data.” Drug Metab Rev 2002; 34:83-448.

Rishton, GM "Reactive compounds and in vitro false positives in HTS", Drug Discovery Today ;2:382-384

Roberts DW et al. “TIMES-SS−A Mechanistic Evaluation of an External Validation Study Using Reaction Chemistry Principles.” Chem Res Toxicol 2007; 20, 1321-1330.

Rodgers T, Leahy D, Rowland M. “Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.” J Pharm Sci. 2005; 94:1259-76

Rodgers T, Leahy D, Rowland M. “Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.” J Pharm Sci. 2005; 94:1237-48.

Rodrigues DA, Roberts EM, Mulford DJ, Yao Y, Ouellet D. “Oxidative Metabolism of Clarithromycin in the Presence of Human Liver Microsomes: Major Role for the Cytochrome P4503A (CYP3A) Subfamily.” Drug Metab Dispos 1997; 25:623.

Rodríguez Sarmiento RM, Bissantz C, Bylund J, Limberg A, Neidhart W, Jakob-Roetne R, Wang L, Baumann K. Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere. J Med Chem 2020;63(15):8534–8553.

Rogers D and Hahn M, "Extended-Connectivity Fingerprints" J. Chem. Inf. Model., 2010; 50:742–754

Rombouts et al., “1,4-Oxazine β‑Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.” J Med Chem, 2015, 58: 8216

Roy K, Mitra I. Electrotopological state atom (E-state) index in drug design, QSAR, property prediction and toxicity assessment. Curr Comput Aided Drug Des 2012; 8:135-58.

Rudik A, Dmitriev A, Lagunin A, Filimonov D, Poroikov V. "SOMP: web server for in silico prediction of sites of metabolism for drug-like compounds." Bioinformatics 2015, 31:2046-2048.

Rupp M, Koerner R, Tetko IV. "Predicting the pKa of Small Molecules." Comb. Chem. High Throughput Screening 2011; 14: 307-327.

Russell S, Norvig P. Artificial Intelligence: A Modern Approach. Prentice Hall (1995).

Russom CL, Bradbury SP, Broderius SJ, Hammermeister DE, and Drummond RA. “Predicting modes of action from chemical structure: Acute toxicity in the fathead minnow (Pimephales promelas).” Env Tox Chem 1997; 16: 948-967.

Rytting E, Lentz KA, Chen XQ, Qian F, Vakatesh S. "Aqueous and cosolvent solubility data for drug-like organic compounds". AAPS J 2005; 7:E78-E105.

Rosipal R, Trejo LJ, “Kernel Partial Least Squares Regression in Reproducing Kernel Hilbert Space.” J Mach Learn Res 2001; 2:97-123.

Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M. "Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450." Xenobiotica 2000; 30:327-343.

Santisteban Valencia Z, Kingston J, Miljković F, et al. Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability. J Med Chem. 2024;67(22):20242-20257. doi:10.1021/acs.jmedchem.4c01642

Sawada H, Takami K, Asahi S. “A Toxicogenomic Approach to Drug-Induced Phospholipidosis: Analysis of Its Induction Mechanism and Establishment of a Novel in Vitro Screening System.” Toxicol Sci 2005; 83:282–292.

Schade M, Scott JS, Hayhow TG, et al. Structural and Physicochemical Features of Oral PROTACs. J Med Chem. 2024;67(15):13106-13116. doi:10.1021/acs.jmedchem.4c01017

Schroeder X. “Estimation of the liquid molal volume at the normal boiling point additive method.” In: An Advanced Treatise on Physical Chemistry, vol. I, Fundamental Principles: the Properties of Gases. Ed. Partington J. Longmans, Green; New York (1949).

Schultz, TW, “TETRATOX: Tetrahymena pyriformis population growth impairment endpoint - A surrogate for fish lethality.” Toxicol Meth 1997; 7:289-309.

Schwebel HJ, van Hoogevest P, Leigh ML, Kuentz M. "The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs." Pharm Dev Technol 2011; 16: 278-286.

Seelig A. “A general pattern for substrate recognition by P-glycoprotein.” Eur J Biochem 1998; 251:252-61.

Settimo L, Bellman K, Knegtel RA. "Comparison of the Accuracy of Experimental and Predicted pKa Values of Basic and Acidic Compounds." Pharm. Res. 2014; 31:1082-1095.

Shaikh N, Sharma M, Garg P. "Selective Fusion of Heterogeneous Classifiers for Predicting Substrates of Membrane Transporters." J Chem Inf Model. 2017, 57:594-607.

Shapley LS. "A Values for n-Person Games." The RAND Corporation Report P-295, 15 pp. (1952).

Shepard TH. Catalog of Teratologic Agents. 5th Edn. The Johns Hopkins University Press, Baltimore, MD (1992).

Sheridan RP, Korzekwa KR, Torres RA, and Walker MJ. “Empirical Regioselectivity Models for Human Cytochromes P450 3A4, 2D6, and 2C9.” J Med Chem 2007; 50:3173-3184.

Shitara Y, Sugiyama. Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions. Pharmacol Therapeut 2017; 177:67-80.

Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB. "Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling". Eur J Pharm Biopharm 2009; 73:107-114.

Sigurdsson, H.H., J. Kirch, and C.M. Lehr, Mucus as a barrier to lipophilic drugs. Int J Pharm, 2013. 453(1): p. 56-64.

Singh B, Diaz-Gonzalez R, Ceballos-Perez G, Rojas-Barros DI, Gunaganti N, Gillingwater K, Martinez-Martinez MS, Manzano P, Navarro M, Pollastri MP. Medicinal Chemistry Optimization of a Diaminopurine Chemotype: Toward a Lead for Trypanosoma brucei Inhibitors. J Med Chem 2020;63(17):9912–9927.

Sjöberg A, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell A-L. “Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique.” Eur J Pharm Sci 2013; 48: 166–180.

Smith AL, D’Angelo ND, Bo YY, Booker SK, Cee VJ, Herberich B, Hong F-T, Jackson CLM, Lanman BA, Liu L, Nishimura N, Pettus LH, Reed AB, Tadesse S, Tamayo NA, Wurz RP, Yang K, Andrews KL, Whittington DA, McCarter JD, Miguel TS, Zalameda L, Jiang J, Subramanian R, Mullady EL, Caenepeel S, Freeman DJ, Wang L, Zhang N, Wu T, Hughes PE, Norman MH. Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases. J Med Chem 2012;55(11):5188–5219.

Smith DA, Obach RS. "Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment." Chem Res Toxicol 2009:22:267–279.

Smola AJ, Scholkopf B. A Tutorial on Support Vector Regression. NeuroCOLT2 Technical Report Series (1998).

Söderholm AA, Johanna V, Lehtovuori PT, Eskelinen H, Roell D, Baniahmad A, Nyrönen TH. “Computationally Identified Novel Diphenyl- and Phenylpyridine Androgen Receptor Antagonist Structures.” J Chem Inf Model 2008, 48: 1882-1890.

Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CECA, Barr JT, Jones JP, Halladay JS. "A Novel Reaction Mediated by Human Aldehyde Oxidase: Amide Hydrolysis of GDC-0834." Drug Metab Dispo 2015, 43:908-915.

Sorich MJ, McKinnon RA, Miners JO, Smith PA. “The Importance of Local Chemical Structure for Chemical Metabolism by Human Uridine 5'-Diphosphate-Glucuronosyltransferase.” J Chem Inf Model 2006; 46:2692-7.

Starrett JEJr, Tortolani DR, Russell J, Hitchcock MJM, Whiterock V, Martin JC, Mansuri MM. Synthesis, Oral Bioavailability Determination, and in vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA). J Med Chem 1994;37(12):1857–1864.

Stuart M, Box K. "Chasing equilibrium: measuring the intrinsic solubility of weak acids and bases." Anal Chem 2005; 77:983-990.

Sun H, Nguyen K, Kerns E, Yan Z, Yu KR, Shah P, Jadhav A, Xu X. Highly predictive and interpretable models for PAMPA permeability. Bioorganic & Medicinal Chemistry 2017;25(3):1266–1276.

Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. "In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media". Eur J Pharm Sci 2005; 24:305-313.

Sussman NB, Arena VC, Yu S, Mazumdar S, Thampatty BP. “Decision tree SAR models for developmental toxicity based on an FDA/TERIS database.” SAR QSAR Env Res 2003; 14:83-96.

Szakacs Z, Noszal B. "Protonation Microequilibrium Treatment of Polybasic Compounds with Any Possible Symmetry." J. Math. Chem. 1999; 26:139-155.

Szakacs Z, Kraszni M, Noszal, B. "Determination of Microscopic Acid-Base Parameters from NMR-pH Titrations." Anal. Bioanal. Chem. 2004; 378:1428-1448.

Tam KY. "Multiwavelength Spectrophotometric Determination of Acid Dissociation Constants. Part VI. Deconvolution of Binary Mixtures of Ionizable Compounds." Anal. Lett. 2000; 33:145-161.

Takano R, Furumoto K, Shiraki K, Takata N, Hayashi Y, Aso Y, Yamashita S. "Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation." Pharm Res 2008; 25:2334-2344.

Tam KY, Quere L. “Multivawelength Spectrophotometric Resolution of the Micro-Equilibria of Cetirizine.” Anal Sci 2001; 17:1203-1208.

Tamayo NA, Bo Y, Gore V, Ma V, Nishimura N, Tang P, Deng H, Klionsky L, Lehto SG, Wang W, Youngblood B, Chen J, Correll TL, Bartberger MD, Gavva NR, Norman MH. Fused Piperidines as a Novel Class of Potent and Orally Available Transient Receptor Potential Melastatin Type 8 (TRPM8) Antagonists. J Med Chem 2012;55(4):1593–1611.

Tatrai P, Schweigler P, Poller B, Domange N, de Wilde R, Hanna I, Gaborik Z, Huth F. A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. Drug Metab Dispo 2019; 47:768-778.

Tear WF, Bag S, Diaz-Gonzalez R, Ceballos-Pérez G, Rojas-Barros DI, Cordon-Obras C, Pérez-Moreno G, García-Hernández R, Martinez-Martinez MS, Ruiz-Perez LM, Gamarro F, Gonzalez Pacanowska D, Caffrey CR, Ferrins L, Manzano P, Navarro M, Pollastri MP. Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5- b ]pyridazines for the Treatment of Human African Trypanosomiasis. J Med Chem 2020;63(2):756–783.

Temesszentandrási-Ambrus C, Nagy G, Bui A, Gáborik Z. “A Unique In Vitro Assay to Investigate ABCB4 Transport Function.” Int. J. Mol. Sci. 2023, 24, 4459.

Tess DA, Ryu S, DiL. "In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species." Pharm Res 2022; 39:1615-1632.

Tess DA, Chang GC, Keefer C, Carlo A, Jones R, Di L. In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance of Human and Preclinical Species with Liver Microsomes and Hepatocytes. AAPS J 2023;25(3):40.

Tetko I, Villa A. “Efficient Partition of Learning Data Sets for Neural Network Training”. Neural Networks 1997; 10: 1361-1374.

Tetko IV. “Associative Neural Network.” Neural Proc Lett 2002; 16:187-199.

Tetko IV. “Neural Network Studies. 4. Introduction to Associative Neural Networks.” J Chem Inf Comput Sci 2002; 42:717-728.

Tetko IV, and Poda GI. "Chapter 15. Property-based logP prediction." In: Molecular Drug Properties: Measurement and Prediction. Ed. Mannhold R. Wiley-VCH, Weinheim, Germany (2007).

Tett SE, Cutler DJ, Day RO, Brown KF, “A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers.” Br J Clin Pharm 1988; 26:303-313.

Thomas J, Majumdar S, Wasdo S, Majumdar A, Sloan K. “The effect of water solubility of solutes on their flux through human skin in vitro: An extended Flynn database fitted to the Roberts-Sloan equation.” Int J Pharm 2007; 339:157-167.

Tobinaga H, Kameyama T, Asahi K, Horiguchi T, Oohara M, Taoda Y, Hata K, Hasegawa T, Tada Y, Kurihara N, Kanda Y, Yagi S, Tomari M, Tanaka Y, Takahashi F, Taniguchi E, Takahara Y, Shimada S, Takeyama C, Yamamoto S, Shinohara S, Kai H. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: Structure-activity relationships of pyrropyrazolone derivatives. Bioorganic & Medicinal Chemistry Letters 2020;30(24):127636.

Todeschini R, Consonni V. Handbook of Molecular Descriptors. Wiley-VCH, Weinheim; 2000.

Tomizawa K, Sugano K, Yamada H, Horii I. “Physicochemical and cell-based approach for early screening of phospholipidosis inducing potential.” J Toxicol Sci 2006; 31:315–324.

Toshimoto K, Wakayama N, Kusama M, Kazuya M, Sugiyama Y, Akiyama Y. "In silico Prediction of Major Drug Clearance Pathways by Support Vector Machines with Feature-Selected Descriptors." Drug Metab Dispos 2014; 42:1811-1819.

Tukey RH, Strassburg CP. "HUMAN UDP-GLUCURONOSYLTRANSFERASES: Metabolism, Expression, and Disease." Annu Rev Pharmacol Toxicol 2000, 40:581-616.

Uchimura T, Motohiro K, Tomohisa S, and Haruki K. “Prediction of human blood-to-plasma drug concentration ratio.” Biopharmaceutics & drug disposition 2010; 31:286-297 .

Vacondio F, Silva C, Mor M, Testa B. “Qualitative structure-metabolism relationships in the hydrolysis of carbamates.” Drug Metab Rev 2010, 42:551-559.

Varma MV, Gardner I, Steyn SJ, et al. “pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.” Mol Pharm. 2012;9(5):1199-1212. doi:10.1021/mp2004912

Varma MV, Steyn SJ, Allerton C, El-Kattan AF. "Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)." Pharm Res 2015; 32:3785-802.

Verma RP, Matthews EJ. "Estimation of the chemical-induced eye injury using a weight-of-evidence (WoE) battery of 21 artificial neural network (ANN) c-QSAR models (QSAR-21): Part I: Irritation potential." Reg Toxicol Pharmacol 2015, 71:318–330.

Vertzoni M, Fotaki N, Kostewicz E, Stippler E, Leuner C, Nicolaides E, Dressman J, Reppas C. "Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects." J Pharm Pharmacol 2004; 56:453-462.

Vinggaard AM, Niemelä J, Wedebye EB, Jensen GE. “Screening of 397 Chemicals and Development of a Quantitative Structure – Activity Relationship Model for Androgen Receptor Antagonism.” Chem Res Toxicol 2008; 21: 813-823.

Waldman M, Fraczkiewicz R, Clark RD. "Tales from the war on error: the art and science of curating QSAR data." J Comput-aided Molec Des 2015; 29:897-910. 

Wei H, Lobenberg R. "Biorelevant dissolution media as a predictive tool for glyburide a class II drug." Eur J Pharm Sci 2006; 29:45-52.

Wenlock M, Tomkinson N, Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds (CHEMBL3301361).

Wienkers LC and Heath TG. “Predicting in vivo drug interactions from in vitro drug discovery data.” Nat Rev Drug Disc 2005; 4:825-833.

Wenlock MC, Carlsson LA. “How Experimental Errors Influence Drug Metabolism and Pharmacokinetic QSAR/QSPR Models.” J. Chem. Inf. Model. 2015; 55:125-134. 

Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE. “Drug-Drug Interactions For UDP-Glucuronosyltransferase Substrates: A Pharmacokinetic Explanation For Typically Observed Low Exposure (AUCI/AUC) Ratios.” Drug Metab Dispos 2004; 32:1201-1208.

Williams RV, DeMarini DM, Stankowski LF Jr, Escobar PA, Zeiger E, Howe J, Elespuru R, Cross KP. "Are all bacterial strains required by OECD mutagenicity test guideline TG471 needed?" Mutat Res. 2019; 848:503081.

Williamson B, Harlfinger S, McGinnity DF. Evaluation of the Disconnect between Hepatocyte and Microsome Intrinsic Clearance and In Vitro In Vivo Extrapolation Performance. Drug Metab Dispos 2020;48(11):1137–1146.

Wold S, Sjostrom M, and Eriksson L. “PLS-regression: a basic tool of chemometrics.” Chemometric Intell Lab Systems 2001; 58:109-130.

Wójcikowski J, Pichard-Garcia L, Maurel P, and Daniel WA. “Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.” Br J Pharmacol 2003; 138:1465-1474.

Wójcikowski J, Pichard-Garcia L, Maurel P, and Daniel WA. “The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.” Eur Neuropsychopharm 2004; 14:199-208.

Wójcikowski J, Boksa J, and Daniel WA. “Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver – A comparison with other phenothiazines.” Biochem Pharmacol 2010; 80:1252-1259.

Wu L, Guo C, Qu Q, Yu J, Chen W, Wang G, Fan L, Li Q, and Zhou H. “Effects of natural products on the function of human organic anion transporting polypeptide 1B1.” Xenobiotica 2012; 42:339-348.

Wu L, Zhang C, He C, Qian D, Lu L, Sun Y, Xu M, Zhuo J, Liu PCC, Klabe R, Wynn R, Covington M, Gallagher K, Leffet L, Bowman K, Diamond S, Koblish H, Zhang Y, Soloviev M, Hollis G, Burn TC, Scherle P, Yeleswaram S, Huber R, Yao W. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. J Med Chem 2021;64(15):10666–10679.

Vacca J. Modulators of hsd17b13 and methods of use thereof. https://patents.google.com/patent/WO2021003295A1/en, Published online January 7, 2021. Accessed January 3, 2024.

Valkó K, Bevan C, Reynolds D. Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC:  A High-Throughput Alternative to log P/log D. Anal Chem. 1997;69(11):2022-2029. doi:10.1021/ac961242d

Xu Y, Li L, Wang Y, Xing J, Zhou L, Zhong D, Luo X, Jiang H, Chen K, Zheng M, Deng P, Chen X. "Aldehyde Oxidase Mediated Metabolism in Drug-like Molecules: A Combined Computational and Experimental Study." J Med Chem 2017, 60:2973-2982.

Yan A and Gasteiger J. "Prediction of Aqueous Solubility of Organic Compounds by Topological Descriptors." QSAR Comb Sci 2003, 22:821-829.

Yazdanian M, Briggs K, Jankovsky C, Hawi A. "The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs." Pharm Res 2004; 21:293-299.

Yoshida F, Topliss JG. “Unified Model for the Corneal Permeability of Related and Diverse Compounds with Respect to Their Physicochemical Properties.” J Pharm Sci 1996; 85:819-823.

Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, and Chiba K. “Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.” Life Sci 2000; 67:175-184.

Youden WJ. “Index for rating diagnostic tests.” Cancer 1950; 3:32-35.

Zadeh LA. “Fuzzy sets.” Inform Control 1965; 8:338-353.

Zanelli U, Caradonna NP, Hallifax D, Turlizzi E, Houston JB, “Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs.“ Drug Metab Dispos 2012, 40:104–110.

Zaretzki, J.; Matlock, M.; Swamidass, S. J. XenoSite: Accurately Predicting CYP-Mediated Sites of Metabolism with Neural Networks. J. Chem. Inf. Model. 2013; 53:3373– 3383.

Zhang J, Zhang Q. Using Seahorse Machine to Measure OCR and ECAR in Cancer Cells (2019). In: Haznadar, M. (eds) Cancer Metabolism. Methods in Molecular Biology, vol 1928. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9027-6_18

Zhang Y, Bachmeier C, Miller DW. “In vitro and in vivo Models for Assessing Drug Efflux Transporter Activity.” Adv Drug Delivery Rev 2003; 55:31-51.

Zhang XD. “Illustration of SSMD, z Score, SSMD*, z* Score, and t Statistic for Hit Selection in RNAi High-Throughput Screens.” J. Bio. Screen. 2011; 16:775-785.

Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper I, Platts JA. Evaluation of Human Intestinal Absorption Data and Subsequent Derivation of a Quantitative Structure-Activity Relationship (QSAR) With the Abraham Descriptors J Pharm Sci 2001; 90:749-784.

Zhao CY, Zhang HX, Zhang XY, Liu MC, Hu ZD, Fan BT. “Application of support vector machine (SVM) for prediction of toxic activity of different data sets.” Toxicol 2006, 217:105-119.

Zhao CB, Boriani E, Chana A, Roncaglioni A, Benfenati E. “A new hybrid system of QSAR models for predicting bioconcentration factors (BCF).” Chemosphere 2008; 73:1701-1707.

Zhu H, Tropsha A, Fourches D, Varnek A, Papa E, Gramatica P, Öberg T, Dao P, Cherkasov A, Tetko IV, “Combinatorial QSAR Modeling of Chemical Toxicants Tested Against Tetrahymena pyriformis.” J Chem Inf Model 2008; 48:766-784.